Wall Street Analysts See a 38.87% Upside in Insulet (PODD): Can the Stock Really Move This High?Zacks Investment Research • 03/28/24
Insulet's Randomized Controlled Trial (OP5-003) Demonstrates Omnipod® 5 Automated Insulin Delivery System is Superior to Pump TherapyBusiness Wire • 03/08/24
Insulet to Present Results from First Omnipod® 5 Randomized Controlled Trial (OP5-003) at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)Business Wire • 03/05/24
Down -15.31% in 4 Weeks, Here's Why You Should You Buy the Dip in Insulet (PODD)Zacks Investment Research • 02/27/24
Insulet Reports Full Year 2023 Revenue Increase of 30% (30% Constant Currency1) and Fourth Quarter 2023 Revenue Increase of 38% Year-Over-Year (37% Constant Currency)Business Wire • 02/22/24
Countdown to Insulet (PODD) Q4 Earnings: A Look at Estimates Beyond Revenue and EPSZacks Investment Research • 02/19/24
Insulet to Present at The Raymond James & Associates 45th Annual Institutional Investors ConferenceBusiness Wire • 02/13/24
Insulet Announces CE Mark Approval of Omnipod® 5 Integration with Abbott FreeStyle Libre 2 Plus SensorBusiness Wire • 02/07/24
Insulet Announces Changes to Board of Directors with Retirements and New AppointmentsBusiness Wire • 01/18/24
Insulet to Announce Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024Business Wire • 01/11/24
Here are Wall Street's favorite stocks in the sector expected to grow profits the most in 2024Market Watch • 01/09/24